PA
SRPT icon

Perceptive Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Perceptive Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-525,683
Closed -$68.1M – 127
2024
Q1 		$68.1M Buy
525,683
+73,810
+16% +$9.04M 1.19% 30
2023
Q4 		$43.6M Buy
451,873
+269,153
+147% +$25.8M 0.97% 33
2023
Q3 		$22.1M Buy
182,720
+101,646
+125% +$11.5M 0.74% 39
2023
Q2 		$9.28M Sell
81,074
-179,784
-69% -$23.2M 0.27% 68
2023
Q1 		$36M Sell
260,858
-388,392
-60% -$50.4M 1.06% 30
2022
Q4 		$84.1M Buy
649,250
+396,250
+157% +$45.9M 2.36% 11
2022
Q3 		$28M Buy
+253,000
New +$25.5M 0.81% 33
2017
Q3 		– Sell
-1,089,961
Closed -$36.7M – 151
2017
Q2 		$36.7M Sell
1,089,961
-681,068
-38% -$22.2M 1.85% 14
2017
Q1 		$52.4M Sell
1,771,029
-998,800
-36% -$30.9M 2.99% 7
2016
Q4 		$76M Sell
2,769,829
-625,407
-18% -$25.1M 5.4% 4
2016
Q3 		$209M Sell
3,395,236
-372,080
-10% -$11.2M 13.46% 1
2016
Q2 		$71.8M Sell
3,767,316
-65,812
-2% -$1.22M 4.98% 5
2016
Q1 		$74.8M Buy
3,833,128
+1,592,200
+71% +$27.8M 6.56% 3
2015
Q4 		$86.5M Sell
2,240,928
-544,000
-20% -$17.6M 6.4% 3
2015
Q3 		$89.4M Sell
2,784,928
-24,600
-0.9% -$835K 7.14% 3
2015
Q2 		$85.5M Buy
2,809,528
+604,876
+27% +$12.4M 5.15% 4
2015
Q1 		$29.3M Sell
2,204,652
-607,700
-22% -$8.1M 2.28% 9
2014
Q4 		$40.7M Buy
2,812,352
+215,661
+8% +$3.65M 3.41% 4
2014
Q3 		$54.8M Buy
2,596,691
+38,213
+1% +$862K 5.55% 4
2014
Q2 		$76.2M Sell
2,558,478
-320,501
-11% -$10.1M 7.48% 1
2014
Q1 		$69.2M Sell
2,878,979
-605,600
-17% -$15.4M 7.27% 3
2013
Q4 		$71M Buy
3,484,579
+712,510
+26% +$21.2M 8.53% 3
2013
Q3 		$131M Buy
2,772,069
+49,981
+2% +$1.92M 10.62% 2
2013
Q2 		$104M Buy
+2,722,088
New +$97.3M 10.44% 2

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors's SRPT Position: Q2 2024 in Review

Perceptive Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 525,683 shares — an estimated $68.1M sold.

Perceptive Advisors first reported a position in SRPT in Q2 2013 and held it in 24 quarters. The position peaked at $209M in Q3 2016. 484 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Perceptive Advisors reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Perceptive Advisors sold 525,683 Sarepta Therapeutics shares in Q2 2024, an estimated $68.1M.
  • Perceptive Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 24 quarters.
  • Perceptive Advisors's Sarepta Therapeutics position peaked at $209M in Q3 2016.
  • 484 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.